About Spermidine/spermine N(1)-acetyltransferase-like protein 1
Spermidine/spermine N(1)-acetyltransferase-like protein 1 (SATL1) is a protein
from Homo sapiens identified by UniProt accession
Q86VE3, 695 residues long.
MolForge cross-references it against 0 known binders and
6 disease associations.
Target properties
| Protein name | Spermidine/spermine N(1)-acetyltransferase-like protein 1 |
|---|
| UniProt accession | Q86VE3 |
|---|
| Gene | SATL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 695 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86VE3-F1 | alphafold | PREDICTED | 47.69 | — |
Amino-acid sequence (695 residues)
MNQSGTNQSS LSDSNQAGIN QPSTNSLGMN QMDMNQGSAS LYEMNQVDMK QPSMSQAGMR QSGTNLPDIN QPDMKQPDTW QLGRSQPGML QQELSQLVLS KAGISQPDPS QPGPSQSGPS QSRMRQIGTN QSGMSQPVMQ QLDSQSGGSQ PSMRQVGTSQ LGTSQIGMSQ PGTWQTGLSQ PVLRQPNMSP PGMWQPGVQQ PGISQQVPSH PDMSQPGMSQ QVPSQPGIRQ PDTSQSCKNQ TDMSQPDANQ SSLSDSNQTG IIQPSPSLLG MNQMDMNQWS ASLYEMNQVD MKQPSMSQAG MRQSGTNLPD INQPGMKQPG TWQLGRSQPG MWPQSLSELV LSEASISQPG PPQRAPSQSG PRQSSTSQAG TNQSGISQPV MWQLDMRQSG GSQPSMRQVG TSQSGTSQIG MSQPGTWQTG LSQPVPRQPN KSPPGMWQRG MWQPGMSQQV PSQLGMRQPG TSQSSKNQTG MSHPGRGQPG IWEPGPSQPG LSQQDLNQLV LSQPGLSQPG RSQPSVSQMG MRQTSMDYFQ IRHAEAGDCP EILRLIKELA ACENMLDAME LTAADLLRDG FGDNPLFYCL IAEVNDQQKP SGKLTVGFAM YYFTYDSWTG KVLYLEDFYV TQAYQGLGIG AEMLKRLSQI AITTQCNCMH FLVVIWNQAS INYYTSRGAL DLSSEEGWHL FRFNREELLD MAWEE
Explore Spermidine/spermine N(1)-acetyltransferase-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets